Literature DB >> 35085776

SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets.

Shuyu Zheng1, Wenyu Wang1, Jehad Aldahdooh1, Alina Malyutina1, Tolou Shadbahr1, Ziaurrehman Tanoli1, Alberto Pessia1, Jing Tang2.   

Abstract

Combinatorial therapies have been recently proposed to improve the efficacy of anticancer treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug combination datasets. Here, we report the major updates to the SynergyFinder R package for improved interpretation and annotation of drug combination screening results. Unlike the existing implementations, the updated SynergyFinder R package includes five main innovations. 1) We extend the mathematical models to higher-order drug combination data analysis and implement dimension reduction techniques for visualizing the synergy landscape. 2) We provide a statistical analysis of drug combination synergy and sensitivity with confidence intervals and P values. 3) We incorporate a synergy barometer to harmonize multiple synergy scoring methods to provide a consensus metric for synergy. 4) We evaluate drug combination synergy and sensitivity to provide an unbiased interpretation of the clinical potential. 5) We enable fast annotation of drugs and cell lines, including their chemical and target information. These annotations will improve the interpretation of the mechanisms of action of drug combinations. To facilitate the use of the R package within the drug discovery community, we also provide a web server at www.synergyfinderplus.org as a user-friendly interface to enable a more flexible and versatile analysis of drug combination data.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  Drug combination sensitivity analysis; Drug combinations; Drug discovery; Synergy modeling; SynergyFinder

Year:  2022        PMID: 35085776     DOI: 10.1016/j.gpb.2022.01.004

Source DB:  PubMed          Journal:  Genomics Proteomics Bioinformatics        ISSN: 1672-0229            Impact factor:   7.691


  16 in total

1.  SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.

Authors:  António J Preto; Pedro Matos-Filipe; Joana Mourão; Irina S Moreira
Journal:  Gigascience       Date:  2022-09-26       Impact factor: 7.658

Review 2.  Evaluation of synergism in drug combinations and reference models for future orientations in oncology.

Authors:  Diana Duarte; Nuno Vale
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-05-12

3.  Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations.

Authors:  Maria E Cilento; Yee Tsuey Ong; Philip R Tedbury; Stefan G Sarafianos
Journal:  Viruses       Date:  2022-05-31       Impact factor: 5.818

4.  CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells.

Authors:  Mathias Schneeweiss-Gleixner; Yüksel Filik; Gabriele Stefanzl; Daniela Berger; Irina Sadovnik; Karin Bauer; Dubravka Smiljkovic; Gregor Eisenwort; Nadine Witzeneder; Georg Greiner; Gregor Hoermann; Ana-Iris Schiefer; Juliana Schwaab; Mohamad Jawhar; Andreas Reiter; Wolfgang R Sperr; Michel Arock; Peter Valent; Karoline V Gleixner
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

5.  Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations.

Authors:  Kunlakanya Jitobaom; Chompunuch Boonarkart; Suwimon Manopwisedjaroen; Nuntaya Punyadee; Suparerk Borwornpinyo; Arunee Thitithanyanont; Panisadee Avirutnan; Prasert Auewarakul
Journal:  BMC Pharmacol Toxicol       Date:  2022-06-18       Impact factor: 2.605

6.  Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the m6A Methylation of RNA in Acute Myeloid Leukemia Cells.

Authors:  Je-Heon Lee; Namjeong Choi; Subin Kim; Mi Sun Jin; Haihong Shen; Yong-Chul Kim
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-01

7.  Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models.

Authors:  Victoria Heredia-Soto; Javier Escudero; María Miguel; Patricia Ruiz; Alejandro Gallego; Alberto Berjón; Alicia Hernández; Marta Martínez-Díez; Shuyu Zheng; Jing Tang; David Hardisson; Jaime Feliu; Andrés Redondo; Marta Mendiola
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

8.  Bipartite network models to design combination therapies in acute myeloid leukaemia.

Authors:  Mohieddin Jafari; Mehdi Mirzaie; Jie Bao; Farnaz Barneh; Shuyu Zheng; Johanna Eriksson; Caroline A Heckman; Jing Tang
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

9.  A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression.

Authors:  Austin G Holmes; J Brandon Parker; Vinay Sagar; Mihai I Truica; Pritin N Soni; Huiying Han; Gary E Schiltz; Sarki A Abdulkadir; Debabrata Chakravarti
Journal:  Sci Adv       Date:  2022-04-27       Impact factor: 14.957

10.  The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA.

Authors:  Miriam Rehberger; Jonas A Schäfer; Anna-Maria Krampitz; Anne Catherine Bretz; Lukas Jost; Torsten Haferlach; Thorsten Stiewe; Andreas Neubauer
Journal:  Hemasphere       Date:  2022-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.